MarketScreener Homepage > Equities > NASDAQ OMX HELSINKI LTD. > Orion Oyj ORNBV FI0009014377

Report

Delayed NASDAQ OMX HELSINKI LTD. - 01/22 11:29:35 am
38.58	EUR		-0.18%

01/20

ORION OYJ : publishes Financial Statement Release for 2020 on Tuesday 9 February 2021

01/18

ORION OYJ : Animal Health and Vetoquinol expand collaboration – Vetoquinol to distribute 's Clevor® in the USA and to distribute Drontal® and Profender® products in Finland, Hungary and Romania

01/12

ORION OYJ : Recommendation by the Nomination Committee concerning the Board of Directors to be elected by the 2021 AGM of Orion Corporation

Summary

Quotes 5-day view Delayed Quote.

Delayed Nasdaq Omx Helsinki Ltd.

01/18/2021	01/19/2021	01/20/2021	01/21/2021	01/22/2021	Date
39.14(c)	39.27(c)	38.76(c)	38.65(c)	38.58(c)	Last
141 926	286 997	255 310	282 155	200 883	Volume
-0.03%	+0.33%	-1.30%	-0.28%	-0.18%	Change

More quotes

Financials

Sales 2020	1 087 M 1 323 M 1 323 M
Net income 2020	234 M 285 M 285 M
Net cash position 2020	131 M 160 M 160 M
P/E ratio 2020	23,2x
Yield 2020	3,85%

Sales 2021	1 058 M 1 288 M 1 288 M
Net income 2021	207 M 252 M 252 M
Net cash position 2021	140 M 170 M 170 M
P/E ratio 2021	26,2x
Yield 2021	3,91%

Capitalization	5 420 M 6 597 M 6 595 M
EV / Sales 2020	4,87x
EV / Sales 2021	4,99x
Nbr of Employees	3 320
Free-Float	86,5%

More Financials

Company

Orion is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows: - generic, OTC and biosimilar drugs (46.3%); - patented prescription products (38.6%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments; - animal products (8.2%); - pharmaceutical ingredients (5.2%); - other (1.7%):...

Sector

Pharmaceuticals

Calendar

02/09 | 11:00am

Ergebnisveröffentlichung

More about the company

Notations Surperformance© of Orion Oyj

Trading Rating :

Investor Rating :

More Ratings

All news about ORION OYJ

01/20	ORION OYJ : publishes Financial Statement Release for 2020 on Tuesday 9 February..	AQ
01/18	ORION OYJ : Animal Health and Vetoquinol expand collaboration – Vetoquinol..	AQ
01/12	ORION OYJ : Recommendation by the Nomination Committee concerning the Board of D..	AQ
2020	NUVO PHARMACEUTICALS INC : . - Miravo Healthcare Ireland Enters into Suvexx Lice..	AQ
2020	ORION OYJ : 8,242 Orion Corporation A shares converted into B shares	AQ
2020	ORION OYJ : invests EUR 17 million in its production plants in Turku	PU
2020	ORION OYJ : Prosecutor pressed charges against a member of Orion's Board of Dire..	PU
2020	ORION OYJ : Prosecutor pressed charges against a member of Orion's Board of Dire..	AQ
2020	Prosecutor pressed charges against a member of Orion's Board of Directors for..	GL
2020	ORION OYJ : Composition of the Nomination Committee of Orion Corporation	PU
2020	ORION OYJ : Composition of the Nomination Committee of Orion Corporation	AQ
2020	Composition of the Nomination Committee of Orion Corporation	GL
2020	ORION OYJ : Finnish drugmaker Orion's third-quarter profit and sales fall	RE
2020	ORION OYJ : Group Interim Report 1-9/2020	PU
2020	ORION OYJ : Group Interim Report 1-9/2020	AQ

More news

News in other languages on ORION OYJ

2020	ORION OYJ : Veröffentlichung des Halbjahresergebnisses
2020	ORION OYJ : publication des résultats semestriels
2020	Les actions hésitantes, la Chine et les résultats en soutien
2019	ORION OYJ : publication des résultats trimestriels
2019	ORION OYJ : Veröffentlichung des Quartalsergebnisses

More news

Analyst Recommendations on ORION OYJ

2020	ORION OYJ : Finnish drugmaker Orion's second-quarter profit, sales beat forecast..	RE
2018	European shares recover from seven-day losing streak	RE
2018	European shares recover from seven-day losing streak	RE

More recommendations

Stock Trading Strategies

	ORION OYJ - 2020
Is the distribution phase coming to an end ?

BUY

More Stock Trading Analysis

Provided by Scoopnest.com

Chart ORION OYJ

Duration : Period :

Orion Oyj Technical Analysis Chart | ORNBV | FI0009014377 | MarketScreener

Full-screen chart

Technical analysis trends ORION OYJ

	Short Term	Mid-Term	Long Term
Trends	Bullish	Neutral	Neutral

Technical analysis

Income Statement Evolution

More Financials

Consensus

Sell

Buy

Mean consensus	HOLD
Number of Analysts	7
Average target price	33,78 €
Last Close Price	38,58 €
Spread / Highest target	8,86%
Spread / Average Target	-12,4%
Spread / Lowest Target	-27,4%

Consensus

EPS Revisions

More Estimates Revisions

Managers and Directors

Name	Title
Timo Antero Lappalainen	President & Chief Executive Officer
Satu Maarit Ahomäki	Senior Vice President-Commercial Operations
Jari Ilmari Karlson	Chief Financial Officer & SVP-Animal Health
Sinikka Markkula	Chief Information Officer
Minna Ruotsalainen	Senior Vice President-Research & Development

More about the company

Sector and Competitors

	1st jan.	Capitalization (M$)

ORION OYJ	2.80%	6 597



JOHNSON & JOHNSON	3.92%	430 552
ROCHE HOLDING AG	3.06%	308 615
NOVARTIS AG	2.73%	220 726
MERCK & CO., INC.	-1.00%	204 882
PFIZER INC.	-0.71%	203 159

More Results